Buprenorphine: a new maintenance opiate?
Heroin-dependent out-patients who had been prescribed buprenorphine by general practitioners took part in a controlled study in which 2 mg or 4 mg of buprenorphine were administered by the sublingual route to assess its acceptability as a maintenance opiate and to determine the effects of its abrupt withdrawal and reintroduction a week later. Subjects who received 4 mg of buprenorphine reported being more intoxicated and having fewer symptoms of opiate withdrawal than did the subjects who received the 2-mg dose. Subjects who received the higher dose also abused opiate and benzodiazepine drugs less frequently. When buprenorphine was ceased abruptly, the subjects reported mild withdrawal discomfort for which many requested symptomatic treatment. The reintroduction of buprenorphine caused their condition to restabilize. The subjects' use of opiate drugs, as shown by urine assay, rose from a prevalence of around 15% of specimens at the beginning to about 50% of specimens at the end of the five-week study period. Sublingual buprenorphine was acceptable to opiate-addicted outpatients as a maintenance treatment. However, daily doses of greater than 4 mg will probably be required to suppress concurrent opiate abuse, and detoxification will need to be undertaken gradually.
D000284:Administration, Oral; D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006556:Heroin Dependence / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009019:Morphinans / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D010352:Patient Dropouts; D011897:Random Allocation; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D011795:Surveys and Questionnaires
D009019:Morphinans; D009294:Narcotics; D002047:Buprenorphine